Metabotropic glutamate receptors (mGluR)

NCFP is a positive allosteric modulator of metabotropic glutamate receptor 5 (mGlu5). This compound enhances the receptor's activity, making it valuable for investigating therapeutic avenues in central nervous system diseases. Its role in modulating mGlu5 function highlights its potential in understanding neurological disorders and developing novel treatments.

L-CCG-I is a selective mGluR2 agonist, characterized by its conformationally restricted glutamate analog structure. Demonstrating a potent activity with an EC50 value of 0.3 nM, L-CCG-I is instrumental for studies exploring the functions and mechanisms of the mGluR family. This compound is valuable for research applications involving neurotransmission and synaptic plasticity related to mGluR2 signaling pathways.

GRN-529 is a negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). It has demonstrated the ability to modulate sleep-wake activity and exhibits anxiolytic effects in rodent models. This compound is of significant interest for research into sleep disorders and anxiety-related conditions, providing insights into mGluR5-targeted therapeutic strategies.

RO4988546 is a negative allosteric modulator (NAM) of metabotropic glutamate receptors 2 and 3 (mGlu2 and mGlu3). This compound decreases the binding affinity of [3H]-LY354740 at the receptor's positive allosteric site, which impacts G protein coupling and intracellular signaling pathways. RO4988546 is valuable for research in developing antidepressants and cognitive enhancers, offering insights into therapeutic mechanisms targeting glutamatergic signaling.

LSP1-2111 is a phosphinic glutamate derivative that functions as an agonist of metabotropic glutamate (mGlu) receptors. This compound demonstrates significant biological activity in modulating neuronal signaling pathways associated with glutamate transmission. It is primarily used in research applications focusing on neurological disorders, synaptic plasticity, and the exploration of mGlu receptor functions.

(S)-4C3HPG, a selective antagonist of metabotropic glutamate receptor 1a (mGluR 1a) and agonist of GluR2, exhibits significant anticonvulsant properties. This compound demonstrates protective effects against audiogenic seizures in DBA/2 mice, making it a valuable tool for research in epilepsy and related neurological disorders. Its dual action on glutamate receptors positions (S)-4C3HPG as a promising candidate for studies aimed at understanding the modulation of excitatory neurotransmission.

ACPT-II is a selective antagonist of group III metabotropic glutamate receptors (mGluRs), notably influencing neurotransmitter release and signaling pathways. This compound exhibits neuroprotective, anticonvulsant, and anxiolytic-like properties, making it valuable for research in neurological disorders. Its unique profile allows for the exploration of glutamatergic modulation in various models of disease.

VU0029251 is a partial antagonist of the metabotropic glutamate receptor subtype 5 (mGluR5), exhibiting a binding affinity with a Ki value of 1.07 μM. It effectively inhibits glutamate-induced calcium mobilization in HEK293 cells expressing rat mGluR5, with an IC50 of 1.7 μM. This compound is valuable for research into mGluR5-related signaling pathways and potential therapeutic applications in neurological disorders.

PF-06422913 is a potent and selective negative allosteric modulator of the metabotropic glutamate receptor 5 (mGluR5). This compound exhibits significant biological activity in modulating glutamatergic signaling, making it valuable in the study of neuropsychiatric disorders. Its applications include investigating therapeutic strategies for conditions such as anxiety and schizophrenia, where mGluR5 activity is implicated.

Desmethyl-YM-298198 is a high-affinity, selective noncompetitive antagonist of the metabotropic glutamate receptor 1 (mGluR1), exhibiting an IC50 value of 16 nM. This compound demonstrates significant analgesic properties in models of neuropathic pain, specifically in Streptozotocin-induced hyperalgesia. It serves as a valuable tool in research aimed at understanding the role of mGluR1 in pain modulation and the development of therapeutic strategies for pain disorders.

A-850002 is a selective antagonist of metabotropic glutamate receptors (mGluRs) with an IC50 of 27 nM. This compound has been shown to significantly reduce spontaneous pain behavior following skin incision in rodent models. A-850002 is suitable for research applications focused on analgesia and the investigation of pain pathways.

(S)-3-Hydroxyphenylglycine is a selective agonist of the metabotropic glutamate receptor 1 (mGluR1). This compound demonstrates significant biological activity in modulating mGluR1 signaling pathways, making it valuable for research focused on neuropharmacology and neural signaling. Its lack of effect on mGlu2 and mGlu4 further underscores its specificity, facilitating studies on mGluR1-related physiological and pathological processes.

Ro4491533 is a selective negative allosteric modulator of the mGluR2 and mGluR3 receptors. It effectively inhibits glutamate-induced calcium mobilization and decreases [35S]GTPγS binding, demonstrating its capacity to modulate glutamatergic signaling. This compound exhibits favorable pharmacokinetic properties, including high oral bioavailability and the ability to penetrate the blood-brain barrier. Additionally, Ro4491533 has shown potential in reversing motor inhibition caused by LY379268 and displays antidepressant effects in various behavioral tests such as the forced swim test and tail suspension test.

(RS)-4C3HPG, or 4-Carboxy-3-hydroxyphenylglycine, serves as a competitive antagonist of the metabotropic glutamate receptor 1 (mGluR1) in the central nervous system and acts as an agonist at mGluR2/3. This compound demonstrates neuroprotective properties in models of acute global ischemia, making it a valuable tool for investigating glutamate receptor signaling and associated neuroprotective mechanisms. Its dual activity presents opportunities for research in neurodegenerative diseases and synaptic modulation.